Clinical Trial Update: Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of irinotecan and gemcitabine for recurrent or progressive Stage III/IV non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED